Section Arrow
Quote
TNXP.NASDAQ
- Tonix Pharmaceuticals Holding Corp
Quotes are at least 15-min delayed:2026/06/06 19:48 EDT
Regular Hours
Last
 11.07
-0.81 (-6.82%)
Day High 
11.905 
Prev. Close
11.88 
1-M High
15.88 
Volume 
481.12K 
Bid
11
Ask
11.15
Day Low
10.87 
Open
11.87 
1-M Low
11.21 
Market Cap 
189.38M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 12.4 
20-SMA 13.26 
50-SMA 13.32 
52-W High 69.97 
52-W Low 10.87 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-14.66/-5.68
Enterprise Value
190.56M
Balance Sheet
Book Value Per Share
14.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
13.11M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BCDABioCardia Inc.1.03+0.111+12.08%-- 
BGMSBio Green Med Solution Inc1.5+0.44+41.51%0.3PE
CMNDClearmind Medicine Inc.3.98+1.07+36.77%-- 
ADTXAditxt Inc.0.0621-0.0149-19.35%-- 
RXRXRecursion Pharmaceuticals3.315-0.485-12.76%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.